MMVdb

MMVdb integrates vaccinomics and RNA-based therapeutic data for seven human-pathogenic mammarenavirus species to support identification of protein-specific epitopes, antigenic and physiochemical properties, and efficacious RNA molecules for viral hemorrhagic fever research.

Key Features:

• Integration of Multi-Omics Data: Consolidates vaccinomics and immune-omics information for seven human-pathogenic mammarenavirus species.
• Epitope Mapping and Vaccine Design: Employs immune-omics algorithms to map protein-specific cytotoxic T lymphocyte, B lymphocyte, helper T-cell, and interferon-inducing epitopes to guide multi-epitope subunit vaccine design.
• Physiochemical and Antigenic Property Analysis: Analyzes physiochemical and antigenic properties of viral proteins relevant to vaccine and therapeutic development.
• RNA-Based Therapeutics Identification: Conducts genome-based analyses to identify and classify small interfering RNA (siRNA), microRNA, and single guide RNA (sgRNA) candidates based on predicted efficacy.
• Datasets and Vaccine Designs: Provides datasets and multi-epitope vaccine designs for computational and experimental research on mammarenaviruses.

Scientific Applications:

• Vaccine Development: Supports design and evaluation of protein-specific multi-epitope subunit vaccines targeting mammarenaviruses.
• RNA Therapeutic Discovery: Enables discovery and prioritization of siRNA, microRNA, and sgRNA candidates against mammarenavirus genomes.
• Antigenicity and Immunogenicity Studies: Facilitates analysis of antigenic landscapes and physiochemical determinants of immunogenic viral proteins.

Methodology:

Applies immune-omics algorithms to map cytotoxic T lymphocyte, B lymphocyte, helper T‑cell, and interferon-inducing epitopes; performs genome-based analyses to identify and classify siRNA, microRNA, and sgRNA by predicted efficacy; and analyzes physiochemical and antigenic properties, integrating vaccinomics and multi-omics data.